During infection or tumor growth, a type of specialized white blood cells called CD8+ T cells rapidly multiply within the spleen and lymph nodes and acquire the ability to kill diseased cells. Some of these killer T cells then migrate where required to vanquish the germs or cancers.
But how do killer T cells “learn” to leave their home base and amass within specific tissues like the skin, gut, and lung, or solid tumors? Finding the factors that cause T cells to function beyond the lymphoid system and in sites of infection or cancer has proven a tough challenge, but it’s essential for developing cancer-fighting immunotherapy strategies.
Writing in the journal Nature, researchers from The Scripps Research Institute and the University of California, San Diego report the discovery that a protein called “Runx3” programs killer T cells to establish residence in tumors and infection sites.
“Runx3 works on chromosomes inside killer T cells to program genes in way that enables the T cells to accumulate in a solid tumor,” said Matthew Pipkin, Ph.D., associate professor in the Department of Immunology and Microbiology on the Florida campus of The Scripps Research Institute.
The paper, “Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumors,” appears in Nature’s Dec. 14 issue.
There are two main strategies in cancer immunotherapy that employ killer T cells, Pipkin said. Checkpoint inhibitor blockade unleashes killer T cells, prompting them to accumulate in tumors more aggressively. Adoptive cell transfer, meanwhile, involves re-infusing a patient’s own immune cells after they have been engineered in the lab to recognize and destroy the patient’s specific cancer.
The adoptive cell transfer strategy has worked stunningly well in some blood cancers associated with the lymphoid system, so far. But there appears to be less efficient activity of T cells in solid tumors, Pipkin said.
“The gene programs and signals for how the T cells take up residence in tissues outside of the general circulation was not really well understood,” Pipkin said.
To discover factors that control T cell residency beyond the lymphoid system, Pipkin’s team worked collaboratively with the laboratory of UC San Diego’s Ananda Goldrath, who compared the gene expression of CD8+ T cells found in non-lymphoid tissue to those found in the general circulation. From a list of potential factors, they employed an RNA interference screening strategy which can test the actual function of thousands of factors simultaneously. Pipkin’s lab had developed the screening strategy in collaboration with Shane Crotty at the La Jolla Institute for Allergy and Immunology.
“We found a distinct pattern,” Pipkin said. “The screens showed that Runx3 is one at the top of a list of regulators essential for T cells to reside in nonlymphoid tissues.” Moreover, Runx3 was able to engage a specific gene program that is found in natural tissue-resident and tumor infiltrating CD8+ T cells, he said.
The group further assessed whether Runx3 had a role in directing white blood cells that attack solid tumors in mouse melanoma models. They found that adoptive cell transfer of cancer-specific killer T cells that overexpressed Runx3 delayed tumor growth and prolonged survival, while mouse models treated with those lacking Runx3 fared much worse than normal.
“If we enhance Runx3 activity in the cells, the tumors are significantly smaller and there is greater survival compared to the control group,” Pipkin said.
Knowing that modulating Runx3 activity in T cells influences their ability to reside in solid tumors opens new opportunities for improving cancer immunotherapy, Pipkin said.
“The upshot is we could probably use Runx3 to reprogram adoptively transferred cells to help drive them to amass in solid tumors,” he said. He added that a collaboration of specialists energized the research. “It was a fantastic collaboration, it all came together very quickly,” Pipkin said.
The Latest on: Cancer immunotherapy
- Global Cancer Immunotherapy Market Outlook Market Dynamics on Mounting Demand, Technological Advancements and Geography in-Depth 2017-2026 on December 15, 2018 at 4:57 am
New York, NY -- (SBWIRE) -- 12/15/2018 -- A new research by MarketResearch.Biz on Cancer Immunotherapy gives complete guidance which provides the most recent Cancer Immunotherapy market patterns like ... […]
- Cancer Immunotherapy Drug Discovery Outsourcing Market is grow with 14.0% CAGR during the forecast time period 2018-2026 on December 14, 2018 at 3:21 am
The global cancer immunotherapy drug discovery outsourcing market size is anticipated to around USD 1.8 billion by 2026, this market is anticipated to grow with 14.0% CAGR during the forecast time per... […]
- Global Dendritic Cell Cancer Immunotherapy Vaccine Market Sales Dosage Price and Clinical Trials Outlook 2024 on December 6, 2018 at 1:09 am
Download Report: https://www.kuickresearch.com/report-global-dendritic-cell-cancer-vaccine-market-dosage-price-and-clinical-trials-outlook-2024.php Conventional therapies like surgery, radiotherapy an... […]
- Dr. Arkenau on the Potential of Immunotherapy in Gastric Cancer on December 5, 2018 at 3:04 pm
Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Cannon Research Institute UK, discusses the potential of immunotherapy in gastric cancer. Immunotherapy has shown benefit in some patients with ... […]
- New Cancer Immunotherapy Approach Turns Immune Cells into Tiny Anti-Tumor Drug Factories on December 4, 2018 at 1:21 pm
Cancer immunotherapy — efforts to better arm a patient’s own immune system to attack tumors — has shown great potential for treating some cancers. Yet immunotherapy doesn’t work for everyone, and some ... […]
- New cancer immunotherapy approach turns human cells into tiny anti-tumor drug factories on December 4, 2018 at 12:30 pm
UC San Diego School of Medicine researchers developed a method to use B cells to manufacture and secrete microRNA-containing vesicles and showed they can inhibit tumor growth in mice. Credit: UC ... […]
- Study: Immunotherapy Better than Chemotherapy for Subtype of Head and Neck Cancer on December 4, 2018 at 11:31 am
A randomized clinical trial involving 97 medical centers in 20 countries, including Moores Cancer Center at UC San Diego Health, found that treating patients who have chemotherapy-resistant head and n... […]
- Global Cancer Immunotherapy Market 2017-2027 Featuring Leading Players - Pfizer, Merck, Amgen and Roche on December 4, 2018 at 10:09 am
The "Cancer Immunotherapy Market" report has been added to ResearchAndMarkets.com's offering. The global Cancer Immunotherapy market reached USD 42,584.18 Million in 2017 by registering a CAGR of 7.5% ... […]
- Researchers extend effectiveness of immunotherapy to more lung cancer patients on December 4, 2018 at 6:11 am
Immunotherapy, the strategy for triggering the patient's own immune system to attack cancer, is proving effective for more tumour types, although to varying degrees. In lung cancer, immunotherapy ... […]
- Cancer Immunotherapy Market, 2027 - ResearchAndMarkets.com on December 4, 2018 at 6:03 am
DUBLIN--(BUSINESS WIRE)--Dec 4, 2018--The "Cancer Immunotherapy Market" report has been added to ResearchAndMarkets.com's offering. The global Cancer Immunotherapy market reached USD 42,584.18 Million ... […]
via Google News and Bing News